- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
The Scientific World Journal
Volume 2012 (2012), Article ID 128182, 4 pages
Holotranscobalamin Is a Useful Marker of Vitamin B12 Deficiency in Alcoholics
1Hematology Unit, Ospedale Madonna delle Grazie, ASM, Matera, Italy
2Laboratory Unit, Ospedale Madonna delle Grazie, ASM, Matera, Italy
3Internal Medicine Unit, Ospedale Madonna delle Grazie, ASM, Matera, Italy
Received 31 October 2011; Accepted 30 November 2011
Academic Editor: Narisa Futrakul
Copyright © 2012 Alberto Fragasso et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Measurement of serum cobalamin (Cbl) levels is the standard investigation for assessing vitamin B12 deficiency. Falsely increased values of Cbl can be caused by alcoholic liver disease. Measurement of total vitamin B12 serum levels might be misleading in alcoholics, because a tissue metabolic deficiency is possible even with normal serum Cbl levels. Holotranscobalamin (HoloTC), the Cbl metabolically active fraction, is considered as a better index of vitamin B12 deficiency. Methods. For assessing vitamin B12 status, we evaluated 22 adult alcoholic male patients by measuring in parallel serum Cbl, serum folate and red blood cell folate levels, HoloTC levels by the AxSYM assay. Results. HoloTC values were reduced in 3 alcoholics with borderline-low Cbl values. Significant positive correlations were found between serum Cbl and HoloTC levels, serum Cbl and gamma-glutamyl transpeptidase (GGT). Conclusion. HoloTC measurement is a useful option for assessing vitamin B12 status in alcoholics, particularly in the subjects with borderline Cbl values and may be considered an early marker of vitamin B12 deficiency.
Measurement of total serum cobalamin (Cbl) is the standard screening test for assessing vitamin B12 deficiency, but a diagnostic “gold standard” for this purpose is still lacking, especially in cases with borderline values. A vitamin B12 deficiency increases the concentration of total plasma homocysteine (tHcy) and methylmalonic acid (MMA), while folate deficiency only increases the concentration of tHcy. Many authors recognize tHcy and MMA as the most sensitive and early indicators of vitamin B12 and folate status [1, 2]. In these studies, the two metabolic markers are more specific than serum Cbl levels; however, this opinion is not unanimous [3, 4]. Vitamin B12 in serum is bound to proteins called transcobalamin (TC): most cobalamin is carried on TC I, also called haptocorrin (HC), and 20–30% is carried on TC II. The TC II-cobalamin complex is called holotranscobalamin (HoloTC), that is, the metabolically active fraction. The HoloTC RIA is the first available method for measurement of HoloTC ; recently, an automated assay for measuring HoloTC on the Abbott AxSYM analyzer has been introduced . HoloTC, or “active” B12, contains the biologically available Cbl; several studies have shown that HoloTC is the earliest and most specific marker of vitamin B12 deficiency [7, 8]. Falsely increased Cbl values are caused by liver diseases ; particularly elevated serum vitamin B12 levels were found in alcoholics with liver disease [10, 11]. In a previous paper, we have shown that some alcohol-dependent patients with megaloblastic anemia may respond to vitamin B12 treatment despite normal cobalamin serum levels . These findings suggest that alcohol consumption may cause falsely normal Cbl serum levels in these patients. In order to evaluate the vitamin B12 status, we have measured the HoloTC levels in 22 alcohol-dependent patients and investigated the association between this parameter, serum Cbl, and other markers of alcohol abuse.
2. Patients and Methods
Twenty actively drinking male patients with alcohol dependence (DSM-IV) were evaluated. All patients had a complete blood count, performed by a Sysmex XE-2100 automated analyzer (Sysmex, Kobe, Japan), and routine biochemistry (Synchron LX20 Pro, Beckman Coulter, Brea, Calif, USA). Serum creatinine concentrations were in the normal range in all patients, but one. In parallel were measured serum Cbl levels (normal range: 200–1100 pg/mL), serum folate (normal range: 3.1–24 ng/mL), and RBC folate levels (normal range: 342–786 ng/mL) by the ADVIA Centaur chemiluminescence assays (Siemens Medical Solution Diagnostics, Tarrytown, NY, USA). HoloTC levels were measured by performing the AXSYM assay (Abbot Laboratories, Abbot Park, Ill, USA), which is based on the microparticle enzyme immunoassay (MEIA). We used an automated assay for HoloTC that can be used on the Abbott AXSYM immunoassay analyser. This method is a 2-step sandwich microparticle enzyme immunoassay. In the first step, a HoloTC-specific antibody immobilized in latex microparticles captures HoloTC in samples of serum. In step 2, the captured HoloTC is detected with a conjugate of alkaline phosphatase and anti-TC antibody. In details, the 4-methylumbelliferyl phosphate is added. The conjugate labelled with alkaline phosphatase catalyzes the removal of phosphate from the substrate, generating the fluorescent 4-methylumbelliferyl. This product is finally measured by the optical method MEIA. According to the literature, a reference interval of 40–200 pmol/L was considered as appropriate [13, 14]. Two patients were HCV positive, none was HbSAg positive. HoloTC was also measured in a nonalcoholic 84-years-old patient with pernicious anemia (PA). The diagnosis of vitamin B12 deficiency was based on the following criteria: serum Cbl levels <200 pg/mL, serum folate normal or increased levels, and RBC folate normal or decreased levels. In patients with low or borderline-low serum Cbl (values between 201 and 300 pg/mL, gray zone), reduced HoloTC levels confirmed the diagnosis of vitamin B12 deficiency. In patients with normal or decreased serum Cbl levels, decreased RBC folate levels, and normal or decreased serum folate levels, a diagnosis of isolate folate deficiency was made. In patients with all these parameters decreased, a diagnosis of combined deficiency was made.
2.1. Statistical Data Analysis
Results are presented as median and range. Pearson correlation analysis and unpaired -test were used. A value less than 0.05 was considered statistically significant. The statistical procedures were performed with SPSS statistical software v11 (SPSS Inc., Chicago, Ill, USA).
Age, hematologic, and metabolic characteristics of the patients are shown in Table 1. Serum folate and RBC folate levels was decreased in 10 and 7 patients, respectively; serum Cbl were low in one patient (196 pg/mL), borderline low in 2 patients (201 pg/mL and 275 pg/mL, resp.), and increased (>1100 pg/mL) in 3 patients. Median serum Cbl levels were in the normal range. Reduced HoloTC levels were found in all patients with low-borderline Cbl levels (Table 2). The patient with 275 pg/mL serum Cbl levels also showed a folate deficiency. In the patient with PA, both serum Cbl and HoloTC levels were very low (63 pg/mL and 3.9 pmol/L, resp.). Out of 22, 14 patients were anemic (Hb < 12.5 g/dL). Anemia was severe (Hb < 8 g/dL) in 3 patients, caused by hemorrhagic gastritis in a patient and multifactorial in the other two (folate deficiency and infective disease, thalassemia and chronic renal insufficiency, resp.); in the remaining ones, a mild anemia was linked to the alcohol abuse, associated to a folate deficiency in 4 patients. A significant positive correlation was found between serum Cbl and HoloTC levels (, ), serum Cbl and GGT (, ); serum Cbl and HoloTC levels were inversely, but not significantly, related with MCV. No significant correlations were found between serum Cbl and HoloTC with serum ferritin, AST and ALT levels.
Measurement of serum Cbl concentration, serum folate levels, and RBC folate levels has been the cornerstone for assessing suspected cases of these vitamins’ deficiency; however, there are major limitations with this approach. Falsely increased Cbl values are caused by myeloproliferative disorders, liver diseases, intestinal bacterial overgrowth, congenital TC II deficiency, nitrous oxide, and other particular clinical and laboratory circumstances [9, 15]. Increased MMA and tHcy together can be found with primary metabolic defects, renal insufficiency, and hypovolemia, while tHcy alone can increase in alcohol abuse, folate, and vitamin B6 deficiency; MMA is considered a sensitive marker of vitamin B12 deficiency, but the test has a limited availability. Furthermore, in the ambulatory care setting not only Cbl, but also MMA and tHcy levels fluctuate with time and neither predict nor preclude the presence of Cbl-responsive hematologic or neurologic disorders . Several authors have suggested that HoloTC is the better index of Cbl deficiency [7, 17] and the earliest marker for vitamin B12 deficiency in populations at risk  and in the elderly . In a previous paper about megaloblastic anemic patients, we found falsely normal serum Cbl levels only in alcoholics ; out of 101 adult patients with megaloblastic anemia, normal Cbl serum levels, normal serum, and RBC folate levels were found only in 3 patients, all alcohol dependent, while in another, alcoholic borderline vitamin B12 serum levels were found. All the four patients responded to cobalamin treatment. In this study, we have evaluated the vitamin B12 status in 22 alcoholics by measuring not only Cbl concentrations, serum folate and RBC folate levels, but also HoloTC levels, with the Abbott AxSYM assay. It has been reported that liver diseases may cause an increase in circulating Cbl [10, 11, 20]. In our study, median serum Cbl levels were 480 pg/mL; in many reports, serum Cbl levels were found higher in alcoholics than in the control group but generally remain in the reference range [21, 22]. A significant positive correlation was found between vitamin B12 and GGT, a marker of recent alcohol abuse, as reported by others [20, 23]. With increasing alcohol-related hepatocellular damage, serum Cbl tends to be higher; increased serum vitamin B12 titres correlate with disease severity, and declining levels were found during remission of the disease . This phenomenon is likely caused by Cbl release during hepatic cytolysis and/or a defective storage that causes vitamin B12 to leak out of the liver into circulation; on the other hand, a diminished concentration of TCII and a reduced clearance of HC may be the result of an impaired synthesizing liver capability [10–20]. Therefore, measurement of total vitamin B12 serum levels might be misleading in alcoholics, because a tissue metabolic deficiency is possible even with normal serum Cbl levels. A significant positive correlation was found between serum Cbl and HoloTC levels, as reported by others using the same immunoenzymatic assay [13, 25]. Reduced HoloTC levels were found in 3 alcohol-dependent patients with borderline-low Cbl levels. The patient with clinical signs of vitamin B12 deficiency (pernicious anemia) showed very low levels of HoloTC. Therefore, HoloTC measurement was useful to identify a suspected vitamin B12 deficiency in alcoholic patients, despite borderline Cbl levels. Our data, despite the small sample number, support the assumption that HoloTC is an early marker for diagnosing B12 deficiency. This is a preliminary report: further confirmation needs to be clarified with more cases. As expected, in our series, folate deficiency was the most common problem (out of 22, we found RBC folate low in 7 patients), but also Cbl deficiency is a nonnegligible matter in these patients. Our findings suggest that in alcoholics caution is urged in the interpretation of these vitamin assays, particularly in the subjects with borderline-low Cbl values. In this subset of patients, HoloTC measurement may be a useful option for assessing vitamin B12 status.
- J. Lindenbaum, D. G. Savage, S. P. Stabler, and R. H. Allen, “Diagnosis of cobalamin deficiency: II. Relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations,” American Journal of Hematology, vol. 34, no. 2, pp. 99–107, 1990.
- D. G. Savage, J. Lindenbaum, S. P. Stabler, and R. H. Allen, “Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies,” The American Journal of Medicine, vol. 96, no. 3, pp. 239–246, 1994.
- I. Chanarin and J. Metz, “Diagnosis of cobalamin deficiency: the old and the new,” British Journal of Haematology, vol. 97, no. 4, pp. 695–700, 1997.
- A. M. Hvas, J. Ellegaard, and E. Nexø, “Increased plasma methylmalonic acid level does not predict clinical manifestations of vitamin B12 deficiency,” Archives of Internal Medicine, vol. 161, no. 12, pp. 1534–1541, 2001.
- M. Ulleland, I. Eilertsen, E. V. Quadros et al., “Direct assay for cobalamin bound to transcobalamin (holo-transcobalamin) in serum,” Clinical Chemistry, vol. 48, no. 3, pp. 526–532, 2002.
- J. Brady, L. Wilson, L. McGregor, E. Valente, and L. Orning, “Active B12: a rapid, automated assay for holotranscobalamin on the abbott AxSYM analyzer,” Clinical Chemistry, vol. 54, no. 3, pp. 567–573, 2008.
- R. Obeid and W. Hermann, “Holotranscobalamin in laboratory diagnosis of cobalamin deficiency compared to total cobalamin and methylmalonic acid,” Clinical Chemistry and Laboratory Medicine, vol. 45, no. 12, pp. 1746–1750, 2007.
- A. M. Hvas and E. Nexo, “Holotranscobalamin—a first choice assay for diagnosing early vitamin B12 deficiency?” Journal of Internal Medicine, vol. 257, no. 3, pp. 289–298, 2005.
- A. A. M. Ermens, L. T. Vlasveld, and J. Lindemans, “Significance of elevated cobalamin (vitamin B12) levels in blood,” Clinical Biochemistry, vol. 36, no. 8, pp. 585–590, 2003.
- H. Baker, C. B. Leevy, B. De Angelis, O. Frank, and E. R. Baker, “Cobalamin (vitamin B12) and holotranscobalamin changes in plasma and liver tissue in alcoholics with liver disease,” Journal of the American College of Nutrition, vol. 17, no. 3, pp. 235–238, 1998.
- L. Bujanda, C. Sarasqueta, I. Gil et al., “Plasma levels of folate and vitamin B12 in patients with chronic liver disease,” Gastroenterologia y Hepatologia, vol. 33, no. 4, pp. 280–287, 2010.
- A. Fragasso, C. Mannarella, A. Ciancio, and A. Sacco, “Functional vitamin B12 deficiency in alcoholics: an intriguing finding in a retrospective study of megaloblastic anemic patients,” European Journal of Internal Medicine, vol. 21, no. 2, pp. 97–100, 2010.
- F. Bamonti, G. A. Moscato, C. Novembrino et al., “Determination of serum holotranscobalamin concentrations with the AxSYM active B12 assay: cut-off point evaluation in the clinical laboratory,” Clinical Chemistry and Laboratory Medicine, vol. 48, no. 2, pp. 249–253, 2010.
- E. Nexo and E. Hoffmann-Lücke, “Holotranscobalamin, a marker of vitamin B-12 status: analytical aspects and clinical utility,” The American Journal of Clinical Nutrition, vol. 94, no. 1, pp. 359S–365S, 2011.
- V. Devalia, “Diagnosing vitamin B-12 deficiency on the basis of serum B-12 assay,” British Medical Journal, vol. 333, no. 7564, pp. 385–386, 2006.
- L. R. Solomon, “Cobalamin-responsive disorders in the ambulatory care setting: unreliability of cobalamin, methylmalonic acid, and homocysteine testing,” Blood, vol. 105, no. 3, pp. 978–985, 2005.
- E. Nexo, A. M. Hvas, Ø. Bleie et al., “Holo-transcobalamin is an early marker of changes in cobalamin homeostasis: a randomized placebo-controlled study,” Clinical Chemistry, vol. 48, no. 10, pp. 1768–1771, 2002.
- W. Herrmann, R. Obeid, H. Schorr, and J. Geisel, “Functional vitamin B12 deficiency and determination of holotranscobalamin in populations at risk,” Clinical Chemistry and Laboratory Medicine, vol. 41, no. 11, pp. 1478–1488, 2003.
- E. Valente, J. M. Scott, P. -M. Ueland, C. Cunningham, M. Casey, and A. M. Molloy, “Diagnostic accuracy of holotranscobalamin, methylmalonic acid, serum cobalamin, and other indicators of tissue vitamin B12 status in the elderly,” Clinical Chemistry, vol. 57, no. 6, pp. 856–863, 2011.
- D. Lambert, S. Benhayoun, C. Adjalla et al., “Alcoholic cirrhosis and cobalamin metabolism,” Digestion, vol. 58, no. 1, pp. 64–71, 1997.
- B. Cylwik, M. Czygier, M. Daniluk, L. Chrostek, and M. Szmitkowski, “Vitamin B12 concentration in the blood of alcoholics,” Polski Merkuriusz Lekarski, vol. 28, no. 164, pp. 122–125, 2010.
- M. L. Cravo, L. M. Gloria, J. Selhub et al., “Hyperhomocysteinemia in chronic alcoholism: correlation with folate, vitamin B-12, and vitamin B-6 status,” The American Journal of Clinical Nutrition, vol. 63, no. 2, pp. 220–224, 1996.
- H. Himmerich, I. Anghelescu, C. Klawe, and A. Szegedi, “Vitamin B12 and hepatic enzyme serum levels correlate in male alcohol-dependent patients,” Alcohol and Alcoholism, vol. 36, no. 1, pp. 26–28, 2001.
- H. Baker, O. Frank, and B. De Angelis, “Plasma vitamin B12 titres as indicators of disease severity and mortality of patients with alcoholic hepatitis,” Alcohol and Alcoholism, vol. 22, no. 1, pp. 1–5, 1987.
- W. Kwang-Sook, K. Kyung-Eun, P. Joon-Seok, J. I. Park, and J. Y. Han, “Relationship between the levels of holotranscobalamin and vitamin B12,” Korean Journal of Laboratory Medicine, vol. 30, no. 2, pp. 185–189, 2010.